セッション情報

ポスター

第58回・2020年・京都
ポスター
ポスター
Small/LargeIntestine/Immunotherapy
開催回
第58回・2020年・京都

Nivolumab (NIVO) + Low-Dose Ipilimumab (IPI) as First-Line Therapy in Microsatellite Instability-High/DNA Mismatch Repair Deficient (MSI-H/dMMR) Metastatic Colorectal Cancer (mCRC): Clinical Update

演題番号 : P-522

André Thierry:1、Heinz-Josef Lenz:2、Sara Lonardi:3、Vittorina Zagonel:3、Eric V. Cutsem:4、Maria L. Limon:5、Ka Yeung Mark Wong:6、Alain Hendlisz:7、Massimo Aglietta:8、García-alfonso Pilar:9、Bart Neyns:10、Andrea Spallanzani:11、Dana B. Cardin:12、Michael J. Overman:13

1:Hôpital Saint Antoine, Assistance Publique Hôpitaux de Paris and Sorbonne Université, Paris, France、2:USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA、3:Istituto Oncologico Veneto IOV-IRCSS, Padova, Italy、4:University Hospitals Gasthuisberg/Leuven and KU Leuven, Leuven, Belgium、5:Hospital Universitario Virgen del Rocio, Sevilla, Spain、6:Westmead Hospital, Sydney, Australia、7:Institut Jules Bordet, Brussels, Belgium、8:Candiolo Cancer Institute and University of Torino Medical School, Candiolo, Italy、9:Hospital Gral Universitario Gregorio Marañon, Madrid, Spain、10:Universitair Ziekenhuis Brussel, Brussels, Belgium、11:University Hospital of Modena, Modena, Italy、12:Vanderbilt-Ingram Cancer Center, Nashville, TN, USA、13:The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Nivolumab (NIVO) + Low-Dose Ipilimumab (IPI) as First-Line Therapy in Microsatellite Instability-High/DNA Mismatch Repair Deficient (MSI-H/dMMR) Metastatic Colorectal Cancer (mCRC): Clinical Update

Nivolumab (NIVO) + low-dose ipilimumab (IPI) in previously treated microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up

演題番号 : P-523

André Thierry:1、Michael J. Overman:2、Sara Lonardi:3、Ka Yeung Mark Wong:4、Heinz-Josef Lenz:5、Fabio Gelsomino:6、Massimo Aglietta:7、Michael A. Morse:8、Eric V. Cutsem:9、Ray Mcdermott:10、Andrew Hill:11、Michael B. Sawyer:12、Alain Hendlisz:13、Bart Neyns:14

1:Hôpital Saint Antoine, Assistance Publique Hôpitaux de Paris and Sorbonne Université, Paris, France、2:MD Anderson Cancer Center, Houston, TX, USA、3:Istituto Oncologico Vento IOV-IRCSS, Padova, Italy、4:Westmead Hospital, Sydney, Australia、5:University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA、6:University Hospital of Modena, Modena, Italy、7:Candiolo Cancer Institute and University of Torino Medical School, Candiolo, Italy、8:Duke University Medical Center, Durham, NC, USA、9:University Hospitals Gasthuisberg/Leuven and KU Leuven, Leuven, Belgium、10:St Vincent's University Hospital and Cancer Trials Ireland, Dublin, Ireland、11:Tasman Oncology Research, Ltd., Southport, Queensland, Australia、12:Cross Cancer Institute and University of Alberta, Edmonton, Alberta, Canada、13:Institut Jules Bordet, Brussels, Belgium、14:University Hospital Brussels, Brussels, Belgium

Nivolumab (NIVO) + low-dose ipilimumab (IPI) in previously treated microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up